Research Paper Volume 15, Issue 17 pp 8664—8691
Pan-cancer analysis and experimental validation revealed the m6A methyltransferase KIAA1429 as a potential biomarker for diagnosis, prognosis, and immunotherapy
Figure 6. Results of GSVA and immunotherapy prediction analysis. (A) Differences in the scores for pathway activity between groups with high and low KIAA1429 expression. dn, down; UV, ultraviolet; v1, version 1; v2, version 2. (B) Kaplan-Meier analysis of the association between KIAA1429 expression and OS in the IMvigor210 cohort. (C) The proportion of BLCA patients who responded to anti-PD-L1 therapy in the low- and high-KIAA1429 subgroups.